Results 31 to 40 of about 299,819 (305)

Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies [PDF]

, 2012
Lentiviral vectors (LVs) are potent gene transfer vehicles frequently applied in research and recently also in clinical trials. Retargeting LV entry to cell types of interest is a key issue to improve gene transfer safety and efficacy.
Abel, Tobias, Brynza, Julia, Buchholz, Christian J., Kneissl, Sabrina, Rasbach, Anke, Schneider-Schaulies, Jürgen   +5 more
core   +3 more sources

ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization

Viruses, 2019
Infection with Zika virus (ZIKV) came first to public attention after it was found to be associated with congenital microcephaly during the outbreak in Brazil (2015–2016). Diagnosis of ZIKV suffers from extensive cross-reactivity with other Flaviviruses,
Sami Akhras, Marie-Luise Herrlein, Fabian Elgner, Thomas Holzhauser, Eberhard Hildt   +4 more
doaj   +1 more source

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. [PDF]

, 2017
Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV).
Ashokkumar, Manickam, Babu, Hemalatha, Buddolla, Viswanath, Chandrasekaran, Padmapriyadarsini, Cheedarla, Narayanaiah, Hanna, Luke Elizabeth, Kailasam, Nandagopal, Precilla, K Lucia, Ramanathan, VD, Sundaramurthi, Jagadish Chandrabose, Swaminathan, Soumya, Vaniambadi, S Kalyanaraman, Vijayan, KK Vidya   +12 more
core   +3 more sources

Feline Immunodeficiency Virus (FIV) Neutralization: A Review

Viruses, 2011
One of the major obstacles that must be overcome in the design of effective lentiviral vaccines is the ability of lentiviruses to evolve in order to escape from neutralizing antibodies.
Margaret J. Hosie, Daniela Pajek, Brian J. Willett, Ayman Samman   +3 more
doaj   +1 more source

Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster.

PLoS ONE, 2023
Despite development of effective SARS-CoV-2 vaccines, a sub-group of vaccine non-responders depends on therapeutic antibodies or small-molecule drugs in cases of severe disease.
Stine Sofie Frank Lende, Nanna Møller Barnkob, Randi Westh Hansen, Harsh Bansia, Mike Vestergaard, Frederik Holm Rothemejer, Anne Worsaae, Deijona Brown, Maria Lange Pedersen, Anna Halling Folkmar Rahimic, Anna Karina Juhl, Torben Gjetting, Lars Østergaard, Amédée Des Georges, Laurent-Michel Vuillard, Mariane Høgsbjerg Schleimann, Klaus Koefoed, Martin Tolstrup   +17 more
doaj   +1 more source

Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts

Translational Oncology, 2017
Chemokines are small soluble molecules that play critical roles in wound healing, infection, and cancer progression. In particular, overexpression of the C-C motif chemokine ligand 2 (CCL2) in multiple cancer types correlates with poor patient prognosis.
Min Yao, Curtis Smart, Qingting Hu, Nikki Cheng   +3 more
doaj   +1 more source

Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein.

PLoS Neglected Tropical Diseases, 2023
Infections with Chikungunya virus, a mosquito-borne alphavirus, cause an acute febrile syndrome often followed by chronic arthritis that persists for months to years post-infection.
John M Powers, Zoe L Lyski, Whitney C Weber, Michael Denton, Magdalene M Streblow, Adam T Mayo, Nicole N Haese, Chad D Nix, Rachel Rodríguez-Santiago, Luisa I Alvarado, Vanessa Rivera-Amill, William B Messer, Daniel N Streblow   +12 more
doaj   +1 more source

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas. [PDF]

, 2019
Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown.
An, Zhiqiang, Fang-Hoover, June, Freed, Daniel C, Fu, Tong-Ming, Li, Fengsheng, Pereira, Lenore, Petitt, Matthew, Tabata, Takako, Wang, Dai   +8 more
core   +1 more source

HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide

Cell Reports, 2023
Summary: Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify HIV-1 transmission has been a long-sought goal.
Shuishu Wang, Flavio Matassoli, Baoshan Zhang, Tracy Liu, Chen-Hsiang Shen, Tatsiana Bylund, Timothy Johnston, Amy R. Henry, I-Ting Teng, Prabhanshu Tripathi, Jordan E. Becker, Anita Changela, Ridhi Chaudhary, Cheng Cheng, Martin Gaudinski, Jason Gorman, Darcy R. Harris, Myungjin Lee, Nicholas C. Morano, Laura Novik, Sijy O’Dell, Adam S. Olia, Danealle K. Parchment, Reda Rawi, Jesmine Roberts-Torres, Tyler Stephens, Yaroslav Tsybovsky, Danyi Wang, David J. Van Wazer, Tongqing Zhou, Nicole A. Doria-Rose, Richard A. Koup, Lawrence Shapiro, Daniel C. Douek, Adrian B. McDermott, Peter D. Kwong   +35 more
doaj   +1 more source